CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 3 TO OPTION AND LICENSE AGREEMENTOption and License Agreement • May 8th, 2023 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 8th, 2023 Company IndustryThis Amendment No. 3 to Option and License Agreement (the “Third Amendment”) is made as of March 17, 2023 (the “Third Amendment Effective Date”), by and between Beam Therapeutics Inc., a Delaware corporation having an office at 238 Main Street, Cambridge, MA 02142 (“Beam”), and Sana Biotechnology, Inc., a Delaware corporation having an office at 188 E Blaine Street, #400, Seattle, WA 98102 (“Sana”). Sana and Beam are referred to in this Third Amendment individually as a “Party” and collectively as the “Parties”.
Consulting AgreementConsulting Agreement • May 8th, 2023 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledMay 8th, 2023 Company Industry JurisdictionThis Consulting Agreement (this “Agreement”) is made effective as of April 29, 2023 (the “Effective Date”) by and between Sana Biotechnology, Inc., a Delaware corporation (the “Company”) and Sunil Agarwal, M.D., an individual (“Consultant”), for the purpose of setting forth the terms and conditions by which the Company will engage the Consultant to perform services on a temporary basis (such services, the “Services”). The Company and Consultant may be referred to herein individually as “Party” or collectively as the “Parties.”
April 15, 2023 Sunil Agarwal RE: Transition Agreement and Release Dear Sunil,Transition Agreement and Release • May 8th, 2023 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledMay 8th, 2023 Company Industry JurisdictionAs we have discussed, your employment with Sana Biotechnology, Inc. (the “Company”) will terminate on April 28, 2023 (the “Separation Date”). The purpose of this letter agreement (this “Agreement”) is to establish an amicable arrangement for ending your employment relationship with the Company, for you to release the Company of any actual or potential claims, to resolve any disputes you may have with the Company regarding your employment or separation from that employment, and to permit you to receive separation pay or other benefits to the extent specified below. With these understandings and in exchange for the promises of you and the Company as set forth below, by timely signing, returning, and not revoking (if applicable) this Agreement, you and the Company agree to the terms specified herein. Please note that you have 21 days from receipt of this Agreement to sign and return this Agreement, but you cannot sign or return this Agreement prior to the Separation Date.